NCT04118036 2025-08-11
Abemaciclib + Pembrolizumab In Glioblastoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
Clinical Trials
22 trialsNCT06328036 2024-12-30
Testing the Combination of Anti-cancer Drugs Tiragolumab and Atezolizumab to Improve Outcomes for Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Withdrawn
NCT05879120 2024-11-20
Randomized Study of Neo-adjuvant and Adjuvant Pembrolizumab With and Without Targeted Blood Brain Barrier Opening Using Exablate MRI-guided Focused Ultrasound (Exablate MRgFUS) for Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01622764 2024-05-06
89Zr-RO5323441 PET Imaging in Glioblastoma
University Medical Center Groningen
Phase 2 Withdrawn
NCT04629209 2023-11-24
A Phase II, Open Label Study of ONC201 in Adults With EGFR-low Glioblastoma
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT02432417 2023-11-18
The Addition of Chloroquine to Chemoradiation for Glioblastoma,
Maastricht Radiation Oncology
Phase 2 Withdrawn
NCT02283944 2021-09-20
TMS Electrochemotherapy for Glioblastoma Multiforme
University of Aarhus
Phase 2 Withdrawn
NCT03506139 2020-09-09
Biologically-based Target Volumes to Treat Newly Diagnosed Glioblastoma
University of Iowa
Phase 2 Withdrawn
NCT03014804 2020-07-24
Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT02754362 2020-01-13
A Toll-like Receptor Agonist as an Adjuvant to Tumor Associated Antigens (TAA) Mixed With Montanide ISA-51 VG With Bevacizumab for Patients With Recurrent Glioblastoma
NYU Langone Health
Phase 2 Withdrawn
NCT00814593 2019-05-10
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
Lisata Therapeutics, Inc.
Phase 2 Withdrawn
NCT01788280 2018-02-07
Preliminary Assessment of [18F] Fluciclatide (GE [18F]AH111585) in Glioblastoma Multiforme Treated With Bevacizumab
University of Utah
Phase 2 Withdrawn
NCT01782976 2018-01-19
Ph II Cilengitide Plus Bevacizumab for Recurrent Glioblastoma (GBM)
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT02977689 2017-12-20
Trial of IDH305 in IDH1 Mutant Grade II or III Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT01413438 2017-07-02
Bevacizumab With or Without Surgery for Adult Glioblastomas
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT02876003 2017-02-24
Efficacy and Safety of G-202 in PSMA-Positive Glioblastoma
GenSpera, Inc.
Phase 2 Withdrawn
NCT01445691 2016-05-17
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
Icahn School of Medicine at Mount Sinai
Phase 2 Withdrawn
NCT00006263 2015-08-05
Carboplatin, Temozolomide, and Filgrastim in Treating Patients With Newly Diagnosed or Recurrent High-Grade Glioma
NYU Langone Health
Phase 2 Withdrawn
NCT01225510 2015-03-11
A Trial Of PF-04856884 In Patients With Recurrent Glioblastoma
Pfizer
Phase 2 Withdrawn
NCT00797940 2012-12-03
CLARITY-1
Protox Inc.
Phase 2 Withdrawn
NCT00005083 2012-10-04
Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors
Jonsson Comprehensive Cancer Center
Phase 2 Withdrawn
NCT00243490 2010-01-12
Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors
National Taiwan University Hospital
Phase 2 Withdrawn